ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

MODAG, H. Lundbeck and Hoffmann-La Roche side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

MODAG×H. Lundbeck×Hoffmann-La Roche×Three at a time for now; Pro will compare up to ten.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

MODAGH. LundbeckHoffmann-La Roche
studies on the registry62762,744
open to participants now310114
phase 3 studies under way0795
reach primary completion within a year3776
programswith a study of their own in two years2680+25 named only

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseMODAGH. LundbeckHoffmann-La Roche
Phase 1

MODAG: 2 of its 2 programs at phase 1

  1. MODAG-009early phase 1
  2. MODAG-005early phase 1
100%

H. Lundbeck: 1 of its 6 programs at phase 1

  1. Lu AH69593phase 1
17%

Hoffmann-La Roche: 33 of its 80 programs at phase 1

  1. RAY121phase 1
  2. clesitamigphase 1
  3. P-CD19CD20-ALLO1 Cellsphase 1
  4. Anti-c-Met Antibody-drug Conjugate YL211phase 1
  5. AQUA07phase 1

and 28 more — sign in to see them all

41%
Phase 200%

H. Lundbeck: 2 of its 6 programs at phase 2

  1. asedebartphase 2
  2. Lu AF28996phase 2
33%

Hoffmann-La Roche: 18 of its 80 programs at phase 2

  1. tifeglipronphase 2
  2. autogene cevumeranphase 2
  3. hyaluronidase (human recombinant)phase 2
  4. RO7568282phase 2
  5. tambotatug pelitecanphase 2

and 13 more — sign in to see them all

23%
Phase 300%

H. Lundbeck: 2 of its 6 programs at phase 3

  1. bexicaserinphase 3
  2. amlenetugphase 3
33%

Hoffmann-La Roche: 22 of its 80 programs at phase 3

  1. inavolisibphase 3
  2. afimkibartphase 3
  3. giredestrantphase 3
  4. divarasibphase 3
  5. glofitamabphase 3

and 17 more — sign in to see them all

28%
Approved, new studies00%

H. Lundbeck: 1 of its 6 programs at approved, new studies

  1. eptinezumabapproved, new study
17%

Hoffmann-La Roche: 7 of its 80 programs at approved, new studies

  1. ocrelizumabapproved, new study
  2. Ranibizumabapproved, new study
  3. emicizumabapproved, new study
  4. faricimabapproved, new study
  5. Trastuzumabapproved, new study

and 2 more — sign in to see them all

9%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
MODAG2 readouts · 0 phase 3······

MODAG, May ’27: 1 program whose next study reaches primary completion

  1. MODAG-009early phase 1 · May 0 · NCT07640555
·

MODAG, Jul ’27: 1 program whose next study reaches primary completion

  1. MODAG-005early phase 1 · Jul 0 · NCT07640542
···
H. Lundbeck5 readouts · 2 phase 3·

H. Lundbeck, Dec ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. bexicaserinphase 3 · Dec 31 · NCT06660394
·

H. Lundbeck, Feb ’27: 1 program whose next study reaches primary completion

  1. Lu AH69593phase 1 · Feb 9 · NCT07613710

H. Lundbeck, Mar ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. eptinezumabapproved, new study · Mar 26 · NCT04965675
·

H. Lundbeck, May ’27: 1 program whose next study reaches primary completion

  1. Lu AF28996phase 2 · May 31 · NCT07513441
··

H. Lundbeck, Aug ’27: 1 program whose next study reaches primary completion

  1. asedebartphase 2 · Aug 10 · NCT06471829
··
Hoffmann-La Roche27 readouts · 7 phase 3

Hoffmann-La Roche, Nov ’26: 1 program whose next study reaches primary completion

  1. divarasibphase 3 · Nov 30 · NCT04302025

Hoffmann-La Roche, Dec ’26: 4 programs whose next study reaches primary completion

  1. RG6496phase 1 · Dec 1 · NCT07246941
  2. tifeglipronphase 2 · Dec 7 · NCT06982131
  3. afimkibartphase 3 · Dec 31 · NCT05910528
  4. inavolisibphase 3 · Dec 31 · NCT03006172

Hoffmann-La Roche, Jan ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. faricimabapproved, new study · Jan 26 · NCT05224102

Hoffmann-La Roche, Feb ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. Ranibizumabapproved, new study · Feb 4 · NCT04657289
  2. cevostamabphase 3 · Feb 26 · NCT05535244

Hoffmann-La Roche, Mar ’27: 4 programs whose next study reaches primary completion

  1. pegozaferminphase 3 · Mar 2 · NCT07835243
  2. glofitamabphase 3 · Mar 22 · NCT06624085
  3. RAY121phase 1 · Mar 31 · NCT06371417
  4. RO7812653phase 1 · Mar 31 · NCT07234942

Hoffmann-La Roche, Apr ’27: 3 programs whose next study reaches primary completion, 2 in phase 3

  1. enicepatidephase 3 · Apr 8 · NCT07626515
  2. Crovalimabphase 3 · Apr 18 · NCT04432584
  3. baloxavirphase 3 · Apr 30 · NCT07827599

Hoffmann-La Roche, May ’27: 1 program whose next study reaches primary completion

  1. RO7806881phase 1 · May 11 · NCT07271693

Hoffmann-La Roche, Jun ’27: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. fenebrutinibphase 3 · Jun 8 · NCT07161258
  2. DONQ52phase 2 · Jun 15 · NCT07239336
  3. RO7890597phase 1 · Jun 15 · NCT07797478
  4. astegolimabphase 3 · Jun 30 · NCT05878769

Hoffmann-La Roche, Jul ’27: 2 programs whose next study reaches primary completion

  1. giredestrantphase 3 · Jul 31 · NCT03332797
  2. trontinemabphase 3 · Jul 31 · NCT04639050

Hoffmann-La Roche, Aug ’27: 2 programs whose next study reaches primary completion

  1. RO7837195phase 2 · Aug 25 · NCT06979336
  2. bizrolertinibphase 3 · Aug 31 · NCT05593094

Hoffmann-La Roche, Sep ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. zemocimigphase 3 · Sep 23 · NCT07416526

Hoffmann-La Roche, Oct ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. mosunetuzumabphase 3 · Oct 1 · NCT05207670
  2. emicizumabapproved, new study · Oct 6 · NCT06998524
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

MODAG

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

H. Lundbeck

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 2

Hoffmann-La Roche

New programs 4

  • RO7836748phase 1 · first study · Oct 23
  • RO7821657phase 1 · first study · Oct 14
  • RO7965032phase 2 · first study · Sep 25 · Geographic Atrophy
  • RO7830698phase 2 · first study · Sep 11 · Pulmonary Disease, Chronic Obstructive

Reached a new phase 1

Study stopped 1

  • RO7763505phase 1 · terminated Nov 17 · none of its studies left running“The development of RO7763505 for coronary artery disease has been discontinued.” · NCT07495813

Primary completion later 11

Where they overlap

Conditions where at least two of them have programs: 2 in all. A program counts in each condition its studies name most.

ConditionMODAGH. LundbeckHoffmann-La Roche
Parkinson Diseaseall three · compare here

MODAG in Parkinson Disease: 1 program

  1. MODAG-005early phase 1

Their studies: MODAG’s studies of Parkinson Disease in search

H. Lundbeck in Parkinson Disease: 2 programs

  1. amlenetugphase 3
  2. Lu AF28996phase 2

Their studies: H. Lundbeck’s studies of Parkinson Disease in search

Hoffmann-La Roche in Parkinson Disease: 3 programs

  1. prasinezumabphase 3
  2. RO7568282phase 2
  3. selnoflastphase 2

Their studies: Hoffmann-La Roche’s studies of Parkinson Disease in search

Multiple System Atrophy2 of 3 · compare here

MODAG in Multiple System Atrophy: 1 program

  1. MODAG-009early phase 1

Their studies: MODAG’s studies of Multiple System Atrophy in search

H. Lundbeck in Multiple System Atrophy: 1 program

  1. amlenetugphase 3

Their studies: H. Lundbeck’s studies of Multiple System Atrophy in search

–

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

No gene two of them both target, among the programs whose target is known.

A target, or a pathogen for a vaccine, known for: MODAG 0 of 2 · H. Lundbeck 1 of 6 · Hoffmann-La Roche 39 of 80 programs (20 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (Hoffmann-La Roche: 25).